Cancer Research
Addition of relacorilant to nab-paclitaxel reduces risk of death by 33 percent compared to treatment with nab-paclitaxel alone (p-value: 0.066), without increased side effects Excluding patients (i) who had not responded to even their first treatment with a platinum-based therapy (“primary platinum-refractory” patients) or (ii) who had received four or more prior lines of therapy,…
CD388 is a drug-Fc conjugate (DFC) from Cidara’s Cloudbreak® platform and is designed to transform the standard of care for seasonal influenza prevention Trial is advancing to dosing subsequent cohorts Initial safety and pharmacokinetics data from study expected in the second half of 2022 Excerpt from the Press Release: SAN DIEGO, March 31, 2022 (GLOBE…
Independent review identified, no safety concerns in trial’s final safety run-in Cohort supported by prior clinical data showing a pelareorep-based combination driving a 90% clinical benefit rate in KRAS-mutated colorectal cancer patients Multi-indication trial being conducted in collaboration with Roche and AIO also includes pancreatic and advanced anal cancer cohorts Excerpt from the Press Release:…
Data to be Presented at Upcoming Annual ASRA Meeting Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Concentric Analgesics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel, non-opioid pain therapeutics, today announced positive results from its recently completed pilot Phase 2 clinical trial of vocacapsaicin in patients undergoing open laparotomy for ventral hernia…
Genentech Provides Update on Phase III SKYSCRAPER-02 Study in Extensive-Stage Small Cell Lung Cancer
SKYSCRAPER-02, the first randomized study of tiragolumab in extensive-stage small cell lung cancer (ES-SCLC), did not meet its co-primary endpoint of progression-free survival ES-SCLC is a hard-to-treat disease and Tecentriq plus chemotherapy remains a standard of care Tiragolumab continues to be evaluated in non-small cell lung cancer and other cancer types through additional Phase III…
Excerpt from the Press Release: BOSTON, March 23, 2022 (GLOBE NEWSWIRE) — TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, in collaboration with teams from, Massachusetts General Hospital, Michigan State University and Northeastern University, published an article in the journal Cancers titled, Clinical Applications of Short Non-Coding RNA-Based Therapies in the…
Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–Kirilys Therapeutics, Inc., a private, preclinical-stage biopharmaceutical company founded by investment firm Catalys Pacific, announced today that the Company completed a seed financing led by Lightspeed Venture Partners. The company licensed its lead compound, KRLS-017, from Ube Industries, Ltd., a premier Japanese chemical manufacturer. The company also completed…
Excerpt from the Press Release: SAN JOSE, Calif.–(BUSINESS WIRE)–Broncus Medical (02216HK), Inc., developer of diagnostic and therapeutic technology for a variety of lung diseases, today announced online publication in the Respirology journal of a global, multicenter study demonstrating the effectiveness of the company’s Archimedes® Virtual Bronchoscopic Navigation (VBN) System in guiding the sampling of peripheral…
CHMP recommendation follows September 2021 U.S. FDA approval of CABOMETYX in this setting – Excerpt from the Press Release: ALAMEDA, Calif.–(BUSINESS WIRE)–Exelixis, Inc. (Nasdaq: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX® (cabozantinib) as…
First two cohorts indicate pelareorep in combination with paclitaxel was well-tolerated with no new safety signals observed to date Trial is designed to satisfy regulatory requirements and accelerate pelareorep’s development in large and rapidly growing pharmaceutical markets, including China, Hong Kong, Macau, Taiwan, Singapore, and South Korea Final cohort’s dosing regimen is equivalent to Oncolytics’ North American phase 2 trial in…